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Abstract
Background: Many individuals diagnosed with Multiple Sclerosis (MS) are sensitive to increased body temperature,
which has been recognized as correlating with the symptom of fatigue. The need to explore this association has
been highlighted. The aim of this study was to investigate the occurrence of heat sensitivity and its relations to
disease course, disability, common MS-related symptoms and ongoing immunosuppressive treatments among
individuals 65 years of age or younger diagnosed with MS.
Methods: A cross-sectional designed survey was undertaken. A questionnaire was sent to MS-patients with an
Expanded Disability Status Score (EDSS) in the interval of 0-6.5 and who were between 20 and 65 years of age,
living in an eastern region of Sweden (n = 334). Besides occurrence of heat sensitivity (Yes/No) and corresponding
questions, the Fatigue Severity Scale (FSS), the MS-related symptom checklist and the Perceived Deficit
Questionnaire (PDQ) were included. Data were analysed in relation to data level using Chi-square, Mann Whitney
U-test, and Student’s t-test. Pearson’s and Spearman’s correlations were calculated. In the logistic regression
analyses (enter) dichotomized MS-symptoms were used as dependent variables, and EDSS, disease-course, time
since onset, heat-sensitivity, age and sex (female/male) were independent variables. In the linear regression
analyses, enter, mean FSS and summarized PDQ were entered as dependent variables and EDSS, disease-course,
time since onset, heat sensitivity, age and sex (female/male) were independent variables.
Results: Of the responding patients (n = 256), 58% reported heat sensitivity. The regression analyses revealed heat
sensitivity as a significant factor relating not only to fatigue (p < 0.001), but also to several other common MS
symptoms such as pain (p < 0.001), concentration difficulties (p < 0.001), and urination urgency (p = 0.009).
Conclusions: Heat sensitivity in MS patients is a key symptom that is highly correlated with disabling symptoms
such as fatigue, pain, concentration difficulty and urination urgency.
Background
Between 60 and 80% of individuals diagnosed with the
neurological disease Multiple Sclerosis (MS) have been
reported as being sensitive to environmental heat [1]. In
a multinational Internet-based survey of MS patients (n
= 2 529), 70% reported that high temperatures worsened
their MS [2]. Clinically, increased body temperature can
result in increased neurological signs and MS symptoms.
Blurred vision, known as Uthoff’s phenomenon and first
described in 1890, is caused by increased body
temperature due to physical exercise or physical restraint
[3]. The body temperature is found to influence nerve
impulses, which are blocked or slowed down in a
damaged nerve [4-6]. After normalization of the tempera-
ture, signs and symptoms improve or disappear [1,3].
Heat sensitivity has been described as a significant
correlate of the symptom of fatigue in MS [5,7-9].
Together with divided attention and reduced muscular
endurance, both heat sensitivity and fatigue have been
reported as predictors of accidental falls [10]. Recently,
Marino [6] stressed that heat sensitivity has been disre-
garded in studies focusing on fatigue.
In studies covering several decades, the occurrence
rate of fatigue among individuals with MS is described
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spective of disease course, already in 1984 Freal and co-
workers [5] reported fatigue as the very first symptom
in about a third of patients. This initial symptom has
been found to persist over the disease trajectory [14,15].
None of these studies, however, has focused on heat
sensitivity.
During recent decades, individuals diagnosed with MS
have had increased opportunities for treatment through
the development of immune-modulating medications.
These products affect the frequency of relapses and slow
the progression of disability. Some immune-modulating
products (e.g. beta-interferon) have side effects of influ-
enza-like symptoms and fatigue, and may also increase
depressive symptoms [16]. However, in treatment with
beta-interferon, the initial side effects of influenza-like
symptoms and perceived fatigue often decrease when
the treatment spans a longer period. Another product,
glatiramer acetate, is clinically considered neutral in this
respect [17]. A relatively new immune-modulating pro-
duct (natalizumab) has been reported to decrease the
symptom of fatigue [18].
T h ea i mo ft h i ss t u d yw a st oi n v e s t i g a t et h eo c c u r -
rence of heat sensitivity and its relations to disease
course, disability, common MS-related symptoms (espe-
cially fatigue), and ongoing immunosuppressive treat-
ments among individuals 65 years of age or younger
diagnosed with MS and living in an eastern county of
Sweden.
Methods
Study group
In order to reach individuals diagnosed with MS living
in the area, a cross-sectional designed survey was under-
taken, addressed to the individuals registered in the
Swedish MS register (SwMS-reg). Together with infor-
mation about the study, a questionnaire and a pre-paid
reply envelope were sent to 334 individuals fulfilling the
following criteria: i) being diagnosed with MS, ii) having
an Expanded Disability Status Score (EDSS) [19] in the
interval 0≤EDSS≤6.5, and iii) being of working age, i.e.
20-65 years, as 65 is the official retirement age. The
questionnaires were distributed during 2007 to indivi-
duals with EDSS 1-6.5, and a complementary distribu-
tion was sent to individuals with EDSS = 0 in 2008. To
those who had not answered within three weeks, one
reminder was sent.
Data collection
The individual’s age, sex, disease course, i.e. relapsing-
remitting (RR), secondary progressive (SP), primary pro-
gressive (PP) and function, measured with the EDSS
[19], together with date of onset of MS, were obtained
from the SwMS register. The diagnostic criteria used in
the SwMS register are both Poser criteria [20] (older
cases) and McDonald criteria [21] (recent time). Second-
ary progressive course of MS (SP) is a clinical neurologi-
cal status whose onset can be hard to pinpoint. In
clinical trials and other studies, this status is often not
defined in detail. In the SwMS register the following
definition is chosen: A phase of the disease where one
can secure a slowly increasing pyramidal para- or even
tetraparesis, sometimes also a bladder syndrome. In
some cases can it be a cerebellar syndrome. A crucial
criterion is that you observe increasing pyramidal (or
cerebellar) symptoms without any signs of bouts [22].
The patients’ EDSS and disease-course are continu-
ously upgraded at physicians call at the neurological
policlinics. For the majority of the participants in this
study, both the EDSS and disease-course had been
determined within a year before the data collection
started. Common background factors, such as civil sta-
tus, family, level of education and ongoing medical
treatment, were requested in the questionnaire. Occur-
rence of heat sensitivity was asked about in a single
question, “Are you sensitive to heat?” (Yes/No), with fol-
low-up questions concerning how this was experienced
when in sunshine, in a warm room, or taking a hot bath
or shower, and what room-temperature the patient pre-
ferred. Occurrence and perceived severity of fatigue
were requested as well. Furthermore, the following
instruments were included: the Fatigue Severity Scale
(FSS) [7,11]; the MS-related symptom checklist [23] and
the Perceived Deficit Questionnaire (PDQ) [24].
In this study, and based on earlier studies [12,14,25],
the EDSS was grouped according to normal neurological
condition (EDSS = 0), mild disability (1.0≤EDSS≤3.5),
moderate disability (4.0≤EDSS≤5.5) and severe disability
(6.0≤EDSS≤6.5).
The FSS [7,11] comprises nine items covering per-
ceived severity of fatigue, and each item is graded from
least fatigue (1) to severe fatigue (7). As in earlier stu-
dies [e.g. [9,14], in this study an FSS mean score ≤4 was
regarded as indicating no fatigue, >4 but <5 borderline
fatigue, and ≥5 severe fatigue. The FSS has been used in
earlier studies in Sweden [14] and is also used clinically.
In this study, concurrent validity was assessed through
correlations between the FSS with questions about the
impact of fatigue on daily life as well as the occurrence
of fatigue, rated on the MS-related symptom checklist
[23], and resulted in r =0 . 7 9 ,( P < 0.01) and r =0 . 7 7( P
< 0.01), respectively. Reliability was assessed using Cron-
bach’s alpha, and the alpha coefficient was 0.93.
The MS-related symptom checklist [23] was used to
report 25 common MS symptoms such as fatigue, weak-
ness in arms and legs, balance problems, pain, numb-
ness, blurred vision, depression and difficulties with
urination such as frequency and urgency. The
Flensner et al. BMC Neurology 2011, 11:27
http://www.biomedcentral.com/1471-2377/11/27
Page 2 of 8occurrence of each symptom was graded in six steps
from never (1) to always (6), which were then dichoto-
mized, into never/sometimes (1-3) to 1 and usually/
always (4-6) to 2. The checklist has been found to be
closely related to the EDSS [23], and has been used in
an earlier study in Sweden [13].
Cognitive dysfunction was assessed using the PDQ
[24], measuring perceived problems with memory, atten-
tion and concentration. The original English version of
the PDQ was translated into Swedish and then back-
translated in accordance with Streiner and Norman [26],
with good agreement. Twenty items are graded from
never (0) to always (4). Summated scores vary from 0 to
80, where higher scores indicate greater cognitive pro-
blems. In this study, concurrent validity, assessed
through correlations between the PDQ sum score and
the MS-related symptoms forgetfulness and concentra-
tion difficulties, was r = 0.75 (P < 0.010) and r = 0.73 (P
< 0.010), respectively. Reliability was tested using Cron-
bach’sa l p h a( a = 0.95) and the split-half technique (r =
0.87).
Statistical analyses
The data have been treated and analysed in relation to
perceived heat sensitivity. The descriptive statistics used
are in congruence with measurement scale level, except
for the FSS which is treated on interval level as in ear-
lier studies [e.g. [9,11,14]. Differences between groups
have been tested using the chi-square test on data on
nominal level, the Mann Whitney U-test on data on
ordinal level, and Student’s t-test on data on interval
level. To test associations between variables, Pearson’s
and Spearman’s correlations were calculated. In the
logistic regression analysis (enter), MS symptoms that
w e r es i g n i f i c a n t l ym o r ef r e quent among heat-sensitive
participants were dichotomized and entered as depen-
dent variables, and EDSS (0-6.5), disease course (relap-
sing-remitting/progressive forms), heat sensitivity (yes/
no), time since onset, and age and sex (female/male)
were independent variables. In the linear regression ana-
lysis (enter) mean FSS and summarized PDQ were
entered as dependent variables and EDSS (0-6.5), disease
course (relapsing/progressive forms), time since onset
and heat sensitivity age and sex (female/male) were
independent variables. In this study, and due to the
number of statistical analyses, a P-value < 0.010 has
been considered a significant value.
Ethical considerations
The study was guided by common ethical principals in
research and according to the Declaration of Helsinki
[27]. Approval to use the SwMS register was received
from the responsible local administrator. The Regional
Ethical Review Board at the Faculty of Health Sciences,
Linköping University, Sweden (Dnr M13-07) also
approved the study. A completed and returned ques-
tionnaire was regarded as granted informed consent.
Results
Study group
Two hundred and fifty-six patients, 195 (76%) women
and 61 (24%) men, aged 65 years or younger and with
an EDSS score between 0 and 6.5, answered the ques-
tionnaires. The response rate was 79.3%. Between parti-
cipants and non-participants there were no statistically
significant differences regarding sex (P = 0.052), disease
course (P = 0.664) or EDSS score (P =0 . 1 4 2 ) .T h en o n -
participants were about five years younger than the par-
ticipants, m = 42.7 years, (SD 10.5) (P < 0.001) and also
had fewer years since onset, Md = 10 (Q1 =5 . 7 5 ;Q 3 =
15.25) (P = 0.014) (Table 1).
Of the participants, the women were somewhat older
(P = 0.022) than the men, 48.3 (SD 11) and 44.8 (SD
10.1), respectively. At onset the median age was 31
years (Q1 = 25; Q3 = 38). In 5.5% of the participants,
onset occurred before 20 years of age, and the youngest
had been 12 years old. The main course of the disease
was relapsing-remitting (73%). Ten percent had an
EDSS score of 0, but most of the patients (61%) had
mild disease severity according to the EDSS. Two hun-
dred and two participants (79%) were being treated
pharmacologically. One hundred and forty-four partici-
pants (56%) were being treated with immune modulat-
ing medication and 32 participants (13%) with
medication for fatigue (Table 1).
Heat sensitivity
One hundred and forty-nine participants (58%) reported
heat sensitivity, with no difference between women and
men (P = 0.102) or in relation to disease course (P =
0.226). In relation to EDSS (Table 1), eight of the partici-
pants (31%) with normal neurological condition, 98
(62%) with mild disability, 16 (53%) with moderate dis-
ability and 27 (63%) with a severe disability reported heat
sensitivity. Of those who were sensitive to heat, 70% pre-
ferred a room temperature of less than 20 C°, while 73%
of those who were not heat sensitive preferred a room
temperature of more than 20°C (P < 0.001). Eleven of the
heat-sensitive participants (n = 149) annotated in the
questionnaire that they also were ‘cold’.
Of common MS-related symptoms, the heat-sensitive
participants reported a significantly higher occurrence of
several symptoms than did those who were not heat sensi-
tive, for example fatigue, weakness in legs, concentration
difficulties, pain, and urination urgency (Table 2). Weak-
ness in arms and legs as well as balance problems corre-
lated significantly with the EDSS, r = 0.17 (p < 0.010), r =
0.49 (p < 0.010), r = 0.51 (p < 0.010), respectively.
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cantly explained several MS symptoms, such as fatigue,
concentration difficulties and pain. Two of the symptoms,
spasms and balance problems, were explained by the
EDSS alone (Table 3) while some were explained by more
than one variable. Together with heat sensitivity and the
EDSS, increasing age also explained the occurrence of
weakness in arms (OR = 1.05, 95%CI = 1.02-1.08, P =
0.001) and urination frequency (OR = 1.04, 95%CI = 1.01-
1.07, P = 0.007). Other interesting findings with regard to
heat sensitivity, EDSS, and increasing age were weakness
in legs (OR = 1.03, 95%CI = 1.0-1.06, P = 0.042) and pain
(OR = 1.04, 95%CI = 1.0-1.07, P = 0.025). Urination
urgency was also explained by gender, female (Or = 0.23,
95%CI = 0.07-0.7, P = 0.01).
The difference in the occurrence of fatigue was con-
firmed by the FSS. Of those who were heat sensitive,
63% reported severe fatigue, FSS≥5, while among those
who were not heat sensitive 45% reported mild or no
fatigue, FSS≤4( P < 0.001) (Table 4). One hundred and
ten (57%) of the women (n = 192) and 21 (35%) of the
men (n = 60) scored an FSS mean value ≥5, classified as
fatigued (P = 0.010). About a third of the participants
who were heat sensitive had concentration difficulties
significantly more often (P < 0.001). This difference was
confirmed by the PDQ, with Md = 29.5 (Q1 = 19; Q3 =
38) among the heat sensitive participants and Md = 21
(Q1 = 12; Q3 = 33) in the non-heat-sensitive participants
(P < 0.001). In the linear regression analyses, heat sensi-
tivity predicted both fatigue and concentration difficul-
ties (Table 5).
There was no difference between heat-sensitive and
non-heat sensitive participants in the use of immune-
modulating drugs or treatment for fatigue. Of those
being treated with the immune-modulating beta-inter-
feron, fewer reported severe fatigue, FSS≥5.0, compared
to those being treated with glatiramer acetate or natali-
zumab (P = 0.021). Of those who were being treated for
fatigue (n = 32) a higher proportion reported severe fati-
gue, FSS≥5.0 (P = 0.016), compared to those not being
treated for fatigue.
Discussion
This is an explorative study aimed at investigating the
occurrence of heat sensitivity in a group of individuals
diagnosed with MS. Further, it aimed to investigate rela-
tions between heat sensitivity and common symptoms
in MS, disease course and disability.
The participants were recruited from the Swedish MS
register in a local county in eastern Sweden. In the cho-
sen EDSS interval, a greater proportion of the patients
had an RR course of the disease and were receiving
immune-modulating treatment, with regular follow-up
visits at the neurological policlinics once a year.
Table 1 Characteristics of the participants (n = 256)
Age, years, Mean (SD) 47 (SD±11)
Women 48.3 (SD
±11)
Men 44.8 (SD
±10.1)
(P=0.022)
Civil status, n (%)
Married/cohabitant 184 (72)
Living alone 72 (28)
Education, n (%)
Lower: Compulsory - Secondary school 168 (66)
Higher: After secondary school - University 88 (34)
Occupation, n (%)
Work 106 (42)
Work and part-time retired or on sick leave 46 (18)
No work 103 (40)
Missing data (n = 1)
Age at onset, year, Md (Q1 ;Q 3 ) 31 (25; 38)
Years since onset of MS symptoms, Md (Q1 ;Q 3) 13 (8; 22)
Course of the disease, n (%)
Relapsing - remitting (RR) 186 (73)
Progressive forms (primary [PP] and
secondary progressive [SP])
70 (27)
Disease severity, n (%)
Normal neurological condition, EDSS = 0 26 (10)
Mild, 1.0≤EDSS≤ 3.5 157 (61)
Moderate, 4.0≤ EDSS≤5.5 30 (12)
Severe, 6.0≤ EDSS≤6.5 43 (17)
Medication, n (%)
No pharmacological treatment 54
(21)
Pharmacological treatment 202
(79)
Immune-modulating treatment 144
(56)
b-interferon 91 (36)
glatiramer acetate 33 (13)
natalizumab 20 (8)
For fatigue 32
(13)
modafinil 32(13)
amantadinchlorid 2(0.7)
Antidepressants 46
(18)
Analgesics 61
(24)
Spasmolytical treatment 36
(14)
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MS and no treatment are seen by general practitioners.
Thus, in this study, there is a selection of patients
towards an RR course of the disease and who are treated
patients. The EDSS scores used were assessed within a
year before the data collection and, thus, there might be
some random variation in the group. However, if any
changes occurred this should be noted in the registry.
Our results indicate that heat sensitivity is highly
correlated with several symptoms commonly reported
by MS patients. That heat sensitivity is associated with
fatigue is well known and has been reported by several
authors [4,6-8]. However, our data also reveal that heat
sensitivity is a key factor associated with the occur-
rence of a wide variety of other MS symptoms, for
example pain, concentration problems and urination
urgency.
Heat sensitivity intensifies MS symptoms
The most striking result in this study is that heat sensi-
tivity significantly correlated with - and in the logistic
regression analyses, appeared as an explaining factor for
- the most incapacitating symptoms of MS, viz. fatigue,
concentration problems and pain. This result discloses
heat sensitivity as a key clinical factor. Our findings are
consistent with a Norwegian study by Nortvedt and co-
workers [28] stating that bodily pain and low vitality are
important problems of MS with a significant impact on
quality of life. Low vitality [28] can be interpreted as
strongly associated to the symptom of fatigue.
We found that many other MS symptoms are also
correlated with heat sensitivity. Interestingly, similar
observations were actually reported in the early works
of Uthoff, although subsequent citations narrowed the
interpretation of Uthoff’s phenomenon to blurring of
the vision [6]. In the present study, however, no rela-
tionship between the symptom of blurred vision and
heat sensitivity was confirmed.
What might be the cause of the observed co-occur-
rence of heat sensitivity and pain, fatigue and cognitive
problems? Can this indicate something about the patho-
genic mechanism? Based on studies of post-stroke
patients, Craig [29] suggests that central pain might be
caused by a thermoregulatory dysfunction. A lesion in
the thalamus releases or disinhibits the feeling of burn-
ing pain by removing the normal inhibition of pain by
cold. The role of the thalamus is as ascending relay of
spinothalamic activity to the cortex [29]. This is similar
to Österberg’s[ 3 0 ]p r o p o s a lt h a tc e n t r a lp a i ni nM S
seems to be generated through lesions affecting the spi-
nothalamo-cortical pathways [30]. A third of the MS
patients with central pain had visible lesions in the tha-
lamus [31]. Thus, one can speculate that the thalamus
might be involved.
Table 2 Significant dichotomized MS symptoms (never to sometimes and usually to always) in relation to reported
heat sensitivity (n = 256)
MS-related symptoms* Appear usually to always n (%) Heat sensitive % P-value
Fatigue 148 (58.5) 68 p<0.001
Leg weakness 144 (57) 66 p=0.003
Concentration difficulties 80 (31) 77.5 p<0.001
Loneliness 31 (12) 81 p=0.010
Pain 74 (29) 78 p<0.001
Paraesthesia 100 (40) 69 p=0.004
Urination urgency 51 (20) 76.5 p=0.004
*) Missing values between two and six.
Table 3 Logistic regression analyses of dichotomized common MS symptoms (1 = never to sometimes, 2 = usually to
always) as dependent variables, and disability (EDSS 0-6.5) and heat sensitivity (1 = yes/0 = no) as independent
variables
MS symptoms EDSS Heat sensitivity R
2 Nagelkerke
OR 95%Cl P-value OR 95%Cl P-value
Fatigue 1.15 0.98-1.32 0.086 2.55 1.48-4.25 <0.001 .136
Leg weakness 1.51 1.26-1.81 <0.001 2.21 1.24-3.93 0.007 .274
Spasms 1.79 1.43-2.22 <0.001 1.65 0.77-3.50 0.194 .232
Balance problems 1.62 1.34-1.94 <0.001 1.48 0.83-2.65 0.181 .285
Concentration difficulties 1.08 0.92-1.28 0.354 3.40 1.85-6.25 <0.001 .123
Pain 1.09 0.92-1.29 0.344 3.55 1.87-6.77 <0.001 .136
Paraesthesia 1.20 1.02-1.41 0.026 2.10 1.21-3.64 0.008 .095
Urination urgency 1.27 1.05-1.54 0.016 2.75 1.28-5.90 0.009 .256
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decreased sweating in terms of electrolytic imbalance
and secondary neuronal effects. Recent results by Saari
and co-workers [32] disclose such an impairment to
thermoregulatory sweating in MS. One idea that may
explain thermoregulatory dysfunction is that lesions can
affect important cerebral areas such as the hypothala-
mus. The study by Saari [32] also demonstrated a corre-
lation between increasing sweating impairment and
increasing disability (EDSS), which is congruent with
our results showing a correlation between heat sensitiv-
ity and increasing EDSS.
Fatigue in MS has been eagerly studied by many
researchers during the past decade. Fatigue and heat
sensitivity are related in many aspects, and a subsequent
question is whether they have common pathogenic fea-
tures. Recently, Marino [6] stated that MS fatigue is
likely to be a central rather than a peripheral phenom-
enon. Heat sensitivity in MS, however, is not understood
as clearly.
The mechanism behind heat sensitivity
The mechanism of heat sensitivity in MS is reviewed in
a recent article by Marino [6]. The heat reaction blocks
the action potential of the demyelinated neuron (fre-
quency-dependent conduction block, - FDCB) [3]. The
demyelinization results in a slower nerve conduction
velocity. A conduction block can occur because the
damaged axons transmit only single or low frequency
impulses, instead of high frequency impulse trains like
in healthy nerve tissue [33]. Marino [6] states that this
observation is very important, especially when an
increase in temperature blocks nerve impulses in
demyelinated fibres [34]. Interestingly, very small
increases in temperature can also block action potentials
[6]. The heat sensitivity in MS is described by Baker as
secondary to both environmental heat and environmen-
tal humidity, as well as to exercise [35]. Both passive
and active body temperature increases give heat reac-
tions. Clinical reports from individual patients in our
MS clinic (i.e. outside this study) reveal that their
experience of temperature aberrations can vary greatly,
indicating that the mechanisms may be multiple.
The subjective phenomenon of heat sensitivity
Many patients with MS are aware of their heat sensitiv-
ity, and have experienced increased clinical symptoms
when becoming warm from fever, hot environmental
temperature or physical exercise. In this study, patients
who did or did not report heat sensitivity were dichoto-
mized and analysed according to this categorization. It
is worth noting that some patients reported both heat
sensitivity and a subjective feeling of “cold”. This sug-
gests that temperature aberrations in MS can be com-
plex and individual. In our clinical practice we also
encounter MS patients with complex subjective tem-
perature aberrations, e.g. patients who deny heat sensi-
tivity when asked, yet prefer to sleep in cold bedrooms
because it alleviates their MS symptoms. Such patients
may not yet be aware of a mild heat sensitivity. This fac-
tor also suggests that milder forms of heat sensitivity
may be underreported in a study like ours. We have
also met one patient who likes to be in the sun all day
without any side effects, but after jogging has to take
repeated showers to prevent incapacitating fatigue.
Finally, it is well known that patients with severe MS
can sometimes develop hypothermia, often without any
major subjective symptoms. We suggest that qualitative
studies should be initiated to describe patients’ experi-
ences of subjective phenomena like heat sensitivity, and
feeling cold as well as combinations of the two. One
cannot exclude that central and peripheral mechanisms
interact in the “temperature syndrome” of MS, which
includes more features than classical heat sensitivity.
Fatigue as a side effect of immune modulating drugs
It has recently been suggested that beta-interferon can
increase fatigue through influenza-like side effects includ-
ing hyperthermia, but that glatiramer-acetate, on the other
hand, is a neutral agent in this respect, and that
Table 4 Fatigue assessed in the Fatigue Severity Scale (FSS)* in relation to reported heat sensitivity (n = 252)**
Non- fatigue
(n = 76)
Borderline fatigue
(n = 45)
Severe fatigue
(n = 131)
Total
n
P-value
Heat sensitive, n (%) 30 (39) 25 (55.5) 94 (72) 149 p<0.001
Not heat sensitive, n (%) 46 (61) 20 (44.5) 37 (28) 103
*FSS≤4 = Non-fatigue; 4 > FSS <5 = Borderline fatigue; FSS≥5 = Severe fatigue;
**Missing value, n = 4.
Table 5 Linear regression analyses of fatigue (FSS) and
perceived deficit questionnaire (PDQ) as dependent
variables and EDSS (0-6.5) and heat sensitivity (yes/no)
as independent variables
EDSS Heat sensitivity
Beta
b
P-value Beta
b
P-value
Fatigue, FSS mean
a) 0.235 0.001 0.321 <0.001
Concentration difficulties, PDQ sum
b) 0.041 0.584 0.215 0.001
a) R 0.421; R
2 0.177; Adjusted R
2 0.161.
b) R 0.239; R 0.057; Adjusted R2 0.038.
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scientific reports support these observations [16-18]. In
our study, however, none of these relationships could be
demonstrated. However, as this study has a descriptive
design, no conclusion regarding what impact immune
modulating treatment has on fatigue could be drawn.
Conclusions
In conclusion, although heat sensitivity in MS was
described as early as the late 19
th century and is a well-
known phenomenon today, it has to date been disre-
garded in studies of fatigue in MS [6]. The findings in
this study underline the importance of heat sensitivity in
MS patients as a key symptom that is highly correlated
with disabling symptoms such as fatigue, concentration
difficulty and urination urgency. A majority of the parti-
cipants rated the symptom of fatigue as their most
impairing symptom. Furthermore, a significantly higher
proportion among the heat-sensitive participants rated
higher levels of fatigue compared to the participants
who were not heat sensitive.
The results of our study put heat sensitivity in the
position of a key clinical symptom. Our findings empha-
size the need to further investigate the mechanism of
heat sensitivity: What is the role of the sweating impair-
ment? Is there thalamic involvement? What is the role
of the immune system? One should also analyse what it
means for patients and in the care of MS patients.
Finally, a challenging topic to investigate is how heat
sensitivity can be treated clinically, for example using
thermotherapy.
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